louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03761121: Developing Fast Pediatric Imaging
Official title: Developing Fast Pediatric Imaging
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pediatric Low-grade Gliomas
Keywords: Neuro Oncology
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
Collaborators: name: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
name: Dana-Farber Cancer Institute
First posted: 2018-12-03
Enrollment: 300
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This research study is evaluating the investigational software for magnetic resonance imaging (MRI) systems and techniques to process magnetic resonance (MR) images

Detailed description: The purpose of the study is to develop new technologies for MRI systems. The new technologies should improve MRI capabilities in terms of how sensitive, specific, and efficient they are. The overall goal is to get better measurements of the brain tumor tissue(s).

In this research study, the investigators want to learn more about investigational software and about techniques to process MR images. The testing of investigational software will allow the investigators to improve the image quality. As part of the testing process, the investigators will collect more MR images of the brain, and improve current image reconstruction methods. This will allow a more precise analysis of MR images and potentially better assessment of the brain tumor tissue volume.

Eligibility criteria: Inclusion Criteria:

* Infants, children and adults who have been diagnosed with Low Grade Glioma
* Healthy volunteers - Children from age 0 to adults with no upper age limit or;
* Diagnosed with LGG and being treated at DFCI;

Exclusion Criteria:

* Electrical implants such as cardiac pacemakers or perfusion pumps;
* Ferromagnetic implants such as aneurysm clips, surgical clips, prosthesis, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants;
* Ferromagnetic objects such as jewelry or metal clips;
* Women of childbearing age who are seeking to become pregnant, who are breastfeeding, or who suspect they may be pregnant;
* Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions;
* Any greater than normal potential for cardiac arrest

Primary outcomes:
measure: Wave-CAIPI validation
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Boston Children Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Boston Children Hospital/ Massachusetts General Hospital
name: Kawin Setsompop, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01302821: C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer
Official title: NCI 8701: A Pilot Study Utilizing C11 Alpha Methyl Tryptophan (AMT) PET Functional Imaging in Patients With Metastatic Invasive Breast Cancer Treated With 1 Methyl D Tryptophan Plus the Ad p53 DC Vaccine
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Breast Cancer
Keywords: breast - male
breast - female
metastatic
invasive
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2011-02-24
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this research project is to create images of where and how the amino acid (the building blocks of proteins)Tryptophan is processed in normal and abnormal tissue in the patient's body. Tryptophan is a normal building block of proteins in the body. Sometimes in the case of cancer and other diseases, Tryptophan is processed abnormally, and possible treatments for this abnormality are of great interest because of the potential to improve cancer care.

Detailed description: Coordinating Center: Southeast Phase 2 Consortium (SEP2C), Moffitt Cancer Center.

Research participation involves up to three experimental imaging examination visits in radiology: a baseline before the patient starts a cancer treatment, a follow-up a few days later, and a later follow up to see how the treatment may affect normal or abnormal processing of Tryptophan.

The research imaging results will be linked with other evidence of the patient's disease, but will not effect their care.

Eligibility criteria: Inclusion Criteria:

* Patients must be enrolled on the NCI 8461/MCC 16025 study.
* Consent for participation in this companion imaging study and be able to successfully complete a minimum of two AMT PET/CT scans.

Exclusion Criteria:

* Patients must not meet any of the exclusion criteria for the NCI 8461/ MCC 16025 study.
* Not have any medical conditions prohibiting the successful completion of a minimum of two AMT PET/CT scans.

Primary outcomes:
measure: Occurrence of Detected Changes in Regions of Interest (ROIs)
timeFrame: Average of 7 weeks
Secondary outcomes:
measure: Number of Participants with Clinical Response
timeFrame: Average of 7 weeks
measure: Number of Participants with Presence of IDO ImmunoHistoChemistry (IHC) Expression
timeFrame: Average of 7 weeks
measure: Number of Participants with Immune Response
timeFrame: Average of 7 weeks
measure: Number of Participants with Adverse Events
timeFrame: Average of 7 weeks
Other outcomes:
Locations:
Study officials:
affiliation: H. Lee Moffitt Cancer Center and Research Institute
name: Hatem Soliman, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01735721: Comparative Study of Algipore and Decalcified Freeze-dried Bone Allograft in Open Maxillary Sinus Augmentation
Official title: Comparative Study of Algipore and Decalcified Freeze-dried Bone Allograft in Open Maxillary Sinus Elevation Using Piezoelectric Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Disorder of Maxillary Sinus
Maxillary Sinus Floor Augmentation
Keywords: Sinus Floor Augmentation
Bone Transplantation
Bone Substitute
Lead sponsor: Mashhad University of Medical Sciences
Sponsor class: OTHER
First posted: 2012-11-28
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of this study was the radiographic and clinical comparison of Algipore with decalcified freeze-dried bone allograft (DFDBA) in the open maxillary sinus lift technique using piezoelectric instruments.

Detailed description: Vertical and horizontal bone resorption of the alveolar ridge are common in edentulous jaws. In the distal area of the maxilla, an adequate bone volume is often lacking because of the proximity of the sinus cavities to crestal bone. Sinus floor augmentation is an established way of increasing the height and volume of bone in the posterior region of the maxilla, which increase the stability of dental implants. For this purpose various materials, including auto grafts, allografts, alloplasts, and xenografts have been used.

Eligibility criteria: Inclusion Criteria:

* physically healthy patients
* ridge bone height of less than 5 mm

Exclusion Criteria:

* any past medical history of systemic or localized diseases that were contraindications for sinus or implant surgery

Primary outcomes:
measure: increase in bone height
timeFrame: 9 months
Secondary outcomes:
measure: Bone Density
timeFrame: 9 months
Other outcomes:
Locations:
city: Mashhad
country: Iran, Islamic Republic of
facility: Amir Moeintaghavi
state: Khorasan Razavi
Study officials:
affiliation: Mashhad University of Medical Sciences
name: Amir Moeintaghavi, DDS., Msc.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04138264: Opioid Counseling Following Orthopaedic Surgery
Official title: Opioid Consumption After Orthopaedic Surgery: Prospective Randomized Trial on the Effects of Pre-Operative Counseling
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Orthopedic Disorder
Lead sponsor: Rothman Institute Orthopaedics
Sponsor class: OTHER
First posted: 2019-10-24
Enrollment: 237
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Postoperative pain management and opioid consumption following outpatient orthopaedic surgery may be influenced by a number of variables including knowledge of safe opioid use. A prospective randomized study is designed to understand the effect of preoperative opioid counseling on postoperative opioid consumption and the typical opioid consumption patterns following common outpatient orthopaedic surgeries. The hypothesis was that patients who received preoperative opioid counseling will consume less postoperative opioid medication and experience greater satisfaction with pain management.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing shoulder, elbow, wrist, knee, foot, and/or ankle surgery

Exclusion Criteria:

* male of female less than 18 years old
* patients schedule to undergo inpatient procedures
* patients undergoing surgeries distal to the wrist
* patients undergoing surgeries under local anesthesia only

Primary outcomes:
measure: Number of pills consumed
timeFrame: Up to 6 weeks
Secondary outcomes:
measure: Morphine equivalents (MEQ)
timeFrame: Up to 6 weeks
measure: Visual Analog Scale (pain) Pain
timeFrame: Up to 6 weeks
measure: Patient satisfaction with pain management: 5 point Likert Scale
timeFrame: Up to 6 weeks
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Rothman Institute
state: Pennsylvania
Study officials:
References:
Clinical trial NCT03180164: Depression in Chronic Airways Diseases
Official title: Anxiety and Depression in Chronic Airways Diseases
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Lung Disease
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2017-06-08
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: Chronic airways diseases involve alterations in the person's social roles, relationships and self-perception so demands continual psychological adjustment .

Also Kunik studied patients with chronic breathing disorders for depression and anxiety and found that 65% of patients were positive for depression and anxiety.

Shackell found that patients' anxiety and fears of breathlessness and dying extended into the night and were aggravated by feelings of isolation and frustration. One patient reported that they often thought 'am I going to see the next morning?'

Detailed description: This fear and sense of helplessness can lead to panic and evidence suggests that patients with chronic breathlessness often call for emergency assistance during the night According to GOLD report 2017, anxiety and depression in chronic obstructive pulmonary disease patients are both associated with poor prognosis.

Much of the evidence explored so far relates to chronic obstructive pulmonary disease. While other chronic lung diseases have received less attention In addition to, several studies have been found relationship between asthma and psychological disturbance .One review of literature describes an increased prevalence of psychological co-morbidity in asthmatic adults and another research suggests that anxiety and depression are more common in patients with moderate to severe asthma than in the general population Gift. found significantly greater self-reported depression scores among patients with chronic obstructive pulmonary disease receiving prednisone compared to patients not receiving any steroids.

Interestingly, the psychiatric sequel of steroid treatment are often sudden in onset and appear to generally occur within 2 weeks after steroid introduction

Eligibility criteria: Inclusion Criteria:

* Chronic airways diseases as chronic obstructive pulmonary disease, bronchial asthma, bronchiectasis

Exclusion Criteria:

* Diabetes Mellitus and Hypertension.
* Cardiac diseases.
* Chronic renal and liver diseases.

Primary outcomes:
measure: compare anxiety and depression in different forms of chronic lung diseases
timeFrame: 10 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Reham Mohamed El-Morshedy
role: STUDY_CHAIR
References:
Clinical trial NCT00909064: The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty
Official title: The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Total Knee Replacement
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2009-05-27
Enrollment: 114
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators hypothesize that Arixtra patients will be less likely to experience wound infection than patients who have received low-molecular weight heparin, coumadin or aspirin with mechanical compression.


Eligibility criteria: Inclusion Criteria:

* All primary unilateral TKA and THA cases will be included.

Exclusion Criteria:

* Patients less than 50 kg, Patients with CrCl\<30ml/min. Revision and bilateral procedures will be excluded.

Primary outcomes:
measure: Number of Days Until a Dry Wound
timeFrame: Up to 10 days
Secondary outcomes:
measure: Number of Days in Hospital.
timeFrame: Up to 10 days
measure: Incidence of Wound Infection
timeFrame: Up to 10 days
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: U C Davis
state: California
Study officials:
affiliation: University of California, Davis Health System
name: Paul E. DiCesare, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06072664: Mother-Baby Study - Caloric Compensation Index (COMPX)
Official title: Fundamental Biobehavioral Mechanisms Underlying the Integrated Development of Emotion, Attachment, and Nutritive Intake in the Mother-Infant Dyad
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Eating Behavior
Keywords: eating behavior
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2023-10-10
Enrollment: 120
Sex: ALL
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The study will test a model of biobehavioral mechanisms involved in the development of a system of emotion, attachment, and nutritive intake in the mother-infant dyad and the association of this system with maternal feeding behavior, child eating behavior, dietary intake, and adiposity.

To participate in this study the infant must also be enrolled in long-term observational study, NCT06039878.

Detailed description: This interventional task is done with children while they are in the long-term observational study, NCT06039878, at approximately ages 18 and 36 months. In the observational study there are 240 participants (120 mothers and 120 children). In this trial only data from the children is collected and therefore only 120 participants are listed.

Eligibility criteria: The child is a participant in the observational study (NCT06039878).

Primary outcomes:
measure: Difference in energy intake of palatable snack following a high-calorie versus low-calorie preload
timeFrame: Up to approximately 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Julie Lumeng, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04255264: Adipose Inflammation and Diabetes (FAB)
Official title: Adipose Tissue Inflammation and Diabetes Development (Fettvävsinflammation Och Diabetesutveckling)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Obese
Lead sponsor: Göteborg University
Sponsor class: OTHER
First posted: 2020-02-05
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The patients participating in this study must have undergone a gastric bypass surgery \>2 years ago, and currently have excess skin of \> 3 cm, thus requiring an abdominoplasty surgery. We only include patients that are obese (BMI 30-40 kg/m2). Patients interested in participating in the study donate the skin and adipose tissue that is discarded during surgery. In addition, they donate blood samples prior to surgery.

Brief summary: The study investigates whether the addition of resolution molecules can inhibit inflammation and insulin resistance in human tissue taken from obese individuals, and whether the results of these studies correlate with patient-specific resolution phenotypes.


Eligibility criteria: Inclusion Criteria:

* BMI 30-40 kg/m2
* Ptos (i.e. excess skin) \> 3 cm
* Patient underwent gastric bypass surgery \>2 years ago
* Patient has had a stable weight ≥6 months at the time of operation
* Patient does not smoke (min 6 weeks prior to surgery)

Exclusion Criteria:

* Patients who do not understand spoken and written Swedish
* American Society of Anesthesiologists (ASA) classification ≥ 3
* Neurological, orthopedic or rheumatologic injury or illness affecting physical ability
* Preoperatively known hernia requiring surgical operation
* Severe mental illness

Primary outcomes:
measure: Inflammatory status
timeFrame: 2025
Secondary outcomes:
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Sahlgrenska university hospital
state: Vastra Gotaland
Study officials:
References:
Clinical trial NCT04292964: Prognostic Factors of Patients With COVID-19
Official title: Prognostic Factors of Patients With COVID-19
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: SARS-CoV-2
Outcome, Fatal
Lead sponsor: Chongqing Medical University
Sponsor class: OTHER
First posted: 2020-03-03
Enrollment: 201
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with COVID-19

Brief summary: The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China has been declared a public health emergency of international concern. Despite lower mortality rate, SARS-CoV-2 has killed more people than SARS and MERS and the number keeps growing. Epidemic studies have been well described clinical features of patients with COVID-19, with the disease severity being an independent predictor of poor outcome. However, there is still no research investigating the prognostic factors of patients with COVID-19.


Eligibility criteria: Inclusion Criteria:

* Adult aged \>=18years old;
* Diagnosed with CONVID19. Diagnostic criteria including: Laboratory (RT-PCR) confirmed SARS-Cov-2 infection; CT of the lung conformed to the manifestation of viral pneumonia.
* Criteria for severe or critical ill conditions: Respiratory rate \>=30/min; or Rest SPO2\<=93%; or PaO2/FiO2\<=300mmHg.

Exclusion Criteria:

* Near-death state (expected survival time less than 24 hours);
* Malignant tumor;
* Pregnancy or puerperium women;
* Patients who refused to participant.

Primary outcomes:
measure: all-cause mortality
timeFrame: 30 days
Secondary outcomes:
measure: all-cause mortality
timeFrame: 15 days
measure: Severe state
timeFrame: 15 days
Other outcomes:
Locations:
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
Study officials:
References:
citation: Wen XS, Jiang D, Gao L, Zhou JZ, Xiao J, Cheng XC, He B, Chen Y, Lei P, Tan XW, Qin S, Zhang DY. Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: a multicenter retrospective study. BMC Infect Dis. 2021 Jan 12;21(1):57. doi: 10.1186/s12879-020-05741-w.
citation: Gao L, Jiang D, Wen XS, Cheng XC, Sun M, He B, You LN, Lei P, Tan XW, Qin S, Cai GQ, Zhang DY. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020 Apr 15;21(1):83. doi: 10.1186/s12931-020-01352-w.
Clinical trial NCT00018564: Novel Therapies for Essential Tremor
Official title: Novel Therapies for Essential Tremor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Essential Tremor
Lead sponsor: VA Office of Research and Development
Sponsor class: FED
First posted: 2001-07-05
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: This clinical research program is designed to evaluate medications as new treatments for essential tremor. Essential tremor is a common condition with few available therapies.

Detailed description: Each medication will be evaluated for effectiveness against tremor in a randomized, placebo-controlled, cross-over, double blind clinical research trial. Tremor will be assessed with accepted rating scales and accelerometry

Eligibility criteria: 1. Diagnosis of essential tremor.
2. Tremor rating scale score 3 or one or both upper extremities
3. Unsatisfactory response to primidone or to propanolol
4. Not taking tremor-inducing drug
5. Able to comply with visits

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: VA Greater Los Angeles Healthcare System
state: California
Study officials:
name: Fredricka Martin, Ph.D.
References: